Amsterdam, the Netherlands, 13 February 2015. LSP (Life Sciences Partners), a leading European investor in health care, today announced that its portfolio company ActoGeniX, a Belgian clinical stage biopharmaceutical company entered into a definitive agreement to be acquired by Intrexon Corporation (NYSE: XON), a leader in synthetic biology.
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases with a high medical need. The addition of the ActoGeniX platform brings two more clinical stage assets to the Intrexon portfolio, and complements the broadest collection of tools available for current and future partners to enable innovative solutions for the next generation of biotechnology.
Consummation of the transaction, anticipated in the first quarter, is subject to customary closing conditions. A version of Intrexon’s press release can be found here.
Since inception, LSP has launched a number funds, follow-on funds and new products, raising in excess of USD 1 billion of investment capital to date. Most recently, LSP had a first closing for its LSP 5 fund. This fund will continue LSP’s proven and successful strategy of investing in emerging private companies with innovative medicines and medical technologies. Other successful investment strategies include LSP’s public healthcare investment activity that has generated triple figure returns over a five year period. As a consequence, LSP has grown to become one of the most successful global healthcare investment groups with 19 exits in the past two years.
Contact
Dr. Anne Portwich, Partner LSP
Tel: +31 (0)20 664 55 00